Cargando…
Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
SIMPLE SUMMARY: Hemangiosarcoma is a mesenchymal neoplasm that originates in the endothelial cells of blood vessels. According to the location of origin, they can be classified as non-visceral and visceral types. Hemangiosarcoma can be very aggressive and metastasize to distant organs. The aim of th...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093745/ https://www.ncbi.nlm.nih.gov/pubmed/37046686 http://dx.doi.org/10.3390/cancers15072025 |
_version_ | 1785023660089671680 |
---|---|
author | De Nardi, Andrigo Barboza de Oliveira Massoco Salles Gomes, Cristina Fonseca-Alves, Carlos Eduardo de Paiva, Felipe Noleto Linhares, Laís Calazans Menescal Carra, Gabriel João Unger dos Santos Horta, Rodrigo Ruiz Sueiro, Felipe Augusto Jark, Paulo Cesar Nishiya, Adriana Tomoko de Carvalho Vasconcellos, Carmen Helena Ubukata, Rodrigo Batschinski, Karen Sobral, Renata Afonso Fernandes, Simone Crestoni Biondi, Luiz Roberto De Francisco Strefezzi, Ricardo Matera, Julia Maria Rangel, Marcelo Monte Mor dos Anjos, Denner Santos Brunner, Carlos Henrique Maciel Laufer-Amorim, Renee Cadrobbi, Karine Germano Cirillo, Juliana Vieira Martins, Mauro Caldas de Paula Reis Filho, Nazilton Silva Lessa, Diego Fernando Portela, Roberta Scarpa Carneiro, Carolina Ricci Lucas, Sílvia Regina Fukumasu, Heidge Feliciano, Marcus Antônio Rossi Gomes Quitzan, Juliany Dagli, Maria Lucia Zaidan |
author_facet | De Nardi, Andrigo Barboza de Oliveira Massoco Salles Gomes, Cristina Fonseca-Alves, Carlos Eduardo de Paiva, Felipe Noleto Linhares, Laís Calazans Menescal Carra, Gabriel João Unger dos Santos Horta, Rodrigo Ruiz Sueiro, Felipe Augusto Jark, Paulo Cesar Nishiya, Adriana Tomoko de Carvalho Vasconcellos, Carmen Helena Ubukata, Rodrigo Batschinski, Karen Sobral, Renata Afonso Fernandes, Simone Crestoni Biondi, Luiz Roberto De Francisco Strefezzi, Ricardo Matera, Julia Maria Rangel, Marcelo Monte Mor dos Anjos, Denner Santos Brunner, Carlos Henrique Maciel Laufer-Amorim, Renee Cadrobbi, Karine Germano Cirillo, Juliana Vieira Martins, Mauro Caldas de Paula Reis Filho, Nazilton Silva Lessa, Diego Fernando Portela, Roberta Scarpa Carneiro, Carolina Ricci Lucas, Sílvia Regina Fukumasu, Heidge Feliciano, Marcus Antônio Rossi Gomes Quitzan, Juliany Dagli, Maria Lucia Zaidan |
author_sort | De Nardi, Andrigo Barboza |
collection | PubMed |
description | SIMPLE SUMMARY: Hemangiosarcoma is a mesenchymal neoplasm that originates in the endothelial cells of blood vessels. According to the location of origin, they can be classified as non-visceral and visceral types. Hemangiosarcoma can be very aggressive and metastasize to distant organs. The aim of this critical review is to present data on the epidemiology, etiology, diagnosis, staging, therapeutic modalities, and prognosis of canine hemangiosarcoma based on a consensus meeting organized by the Brazilian Association of Veterinary Oncology (ABROVET) in September 2022. Recent information from the literature, as well as new results from consensus participants, are presented and discussed. ABSTRACT: Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease. |
format | Online Article Text |
id | pubmed-10093745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100937452023-04-13 Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET De Nardi, Andrigo Barboza de Oliveira Massoco Salles Gomes, Cristina Fonseca-Alves, Carlos Eduardo de Paiva, Felipe Noleto Linhares, Laís Calazans Menescal Carra, Gabriel João Unger dos Santos Horta, Rodrigo Ruiz Sueiro, Felipe Augusto Jark, Paulo Cesar Nishiya, Adriana Tomoko de Carvalho Vasconcellos, Carmen Helena Ubukata, Rodrigo Batschinski, Karen Sobral, Renata Afonso Fernandes, Simone Crestoni Biondi, Luiz Roberto De Francisco Strefezzi, Ricardo Matera, Julia Maria Rangel, Marcelo Monte Mor dos Anjos, Denner Santos Brunner, Carlos Henrique Maciel Laufer-Amorim, Renee Cadrobbi, Karine Germano Cirillo, Juliana Vieira Martins, Mauro Caldas de Paula Reis Filho, Nazilton Silva Lessa, Diego Fernando Portela, Roberta Scarpa Carneiro, Carolina Ricci Lucas, Sílvia Regina Fukumasu, Heidge Feliciano, Marcus Antônio Rossi Gomes Quitzan, Juliany Dagli, Maria Lucia Zaidan Cancers (Basel) Review SIMPLE SUMMARY: Hemangiosarcoma is a mesenchymal neoplasm that originates in the endothelial cells of blood vessels. According to the location of origin, they can be classified as non-visceral and visceral types. Hemangiosarcoma can be very aggressive and metastasize to distant organs. The aim of this critical review is to present data on the epidemiology, etiology, diagnosis, staging, therapeutic modalities, and prognosis of canine hemangiosarcoma based on a consensus meeting organized by the Brazilian Association of Veterinary Oncology (ABROVET) in September 2022. Recent information from the literature, as well as new results from consensus participants, are presented and discussed. ABSTRACT: Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease. MDPI 2023-03-29 /pmc/articles/PMC10093745/ /pubmed/37046686 http://dx.doi.org/10.3390/cancers15072025 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review De Nardi, Andrigo Barboza de Oliveira Massoco Salles Gomes, Cristina Fonseca-Alves, Carlos Eduardo de Paiva, Felipe Noleto Linhares, Laís Calazans Menescal Carra, Gabriel João Unger dos Santos Horta, Rodrigo Ruiz Sueiro, Felipe Augusto Jark, Paulo Cesar Nishiya, Adriana Tomoko de Carvalho Vasconcellos, Carmen Helena Ubukata, Rodrigo Batschinski, Karen Sobral, Renata Afonso Fernandes, Simone Crestoni Biondi, Luiz Roberto De Francisco Strefezzi, Ricardo Matera, Julia Maria Rangel, Marcelo Monte Mor dos Anjos, Denner Santos Brunner, Carlos Henrique Maciel Laufer-Amorim, Renee Cadrobbi, Karine Germano Cirillo, Juliana Vieira Martins, Mauro Caldas de Paula Reis Filho, Nazilton Silva Lessa, Diego Fernando Portela, Roberta Scarpa Carneiro, Carolina Ricci Lucas, Sílvia Regina Fukumasu, Heidge Feliciano, Marcus Antônio Rossi Gomes Quitzan, Juliany Dagli, Maria Lucia Zaidan Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET |
title | Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET |
title_full | Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET |
title_fullStr | Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET |
title_full_unstemmed | Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET |
title_short | Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET |
title_sort | diagnosis, prognosis, and treatment of canine hemangiosarcoma: a review based on a consensus organized by the brazilian association of veterinary oncology, abrovet |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093745/ https://www.ncbi.nlm.nih.gov/pubmed/37046686 http://dx.doi.org/10.3390/cancers15072025 |
work_keys_str_mv | AT denardiandrigobarboza diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT deoliveiramassocosallesgomescristina diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT fonsecaalvescarloseduardo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT depaivafelipenoleto diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT linhareslaiscalazansmenescal diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT carragabrieljoaounger diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT dossantoshortarodrigo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT ruizsueirofelipeaugusto diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT jarkpaulocesar diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT nishiyaadrianatomoko diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT decarvalhovasconcelloscarmenhelena diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT ubukatarodrigo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT batschinskikaren diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT sobralrenataafonso diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT fernandessimonecrestoni diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT biondiluizroberto diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT defranciscostrefezziricardo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT materajuliamaria diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT rangelmarcelomontemor diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT dosanjosdennersantos diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT brunnercarloshenriquemaciel diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT lauferamorimrenee diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT cadrobbikarinegermano diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT cirillojulianavieira diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT martinsmaurocaldas diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT depaulareisfilhonazilton diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT silvalessadiegofernando diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT portelaroberta diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT scarpacarneirocarolina diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT riccilucassilviaregina diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT fukumasuheidge diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT felicianomarcusantoniorossi diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT gomesquitzanjuliany diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet AT daglimarialuciazaidan diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet |